HOME >> MEDICINE >> NEWS
Survival benefit for rheumatoid arthritis patients treated with methotrexate

The anticancer drug methotrexate could have a substantial survival benefit among patients with rheumatoid arthritis, conclude authors of a prospective US study in this weeks issue of THE LANCET.

Rheumatoid arthritis is a chronic inflammatory disease which results in reduced life-expectancy and is associated with cardiovascular disease, infection, and cancer. Low-dose methotrexate is the main choice of antirheumatic therapy for rheumatoid arthritis, although its effect on mortality for patients with the disease is not known.

Hyon Choi from Harvard Medical School and Harvard School of Public Health, Frederick Wolfe from University of Kansas School of Medicine, USA, and colleagues prospectively studied 1240 patients with rheumatoid arthritis over the past two decades. 191 individuals died during follow-up. Patients who began treatment with methotrexate (around half of the study population) had more severe rheumatoid arthritis. After adjustment for this confounding factor, methotrexate was found to have a 60% survival benefit for all-cause mortality compared with those who did not use methotrexate, and a 70% survival benefit for cardiovascular death.

Hyon Choi comments: Our data indicate that methotrexate may provide a substantial survival benefit, largely by reducing cardiovascular mortality. This gain in life expectancy could be considered in selecting a cost-effective, disease-modifying antirheumatic drug on a long-term basis. Additionally, the survival benefit of methotrexate would set a standard against which new disease-modifying antirheumatic drugs should be compared.


'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-0-20-7424-4949
Lancet
4-Apr-2002


Page: 1

Related medicine news :

1. Survival sex and substance abuse may hinder HIV prevention efforts
2. Survival improves in clinical trial for severe birth defect, with or without fetal surgery
3. Abgenix Reports Positive Survival Data From A Phase II Trial Of ABX-CBL In Graft Versus Host Disease
4. American Heart Association Comment: Contributions Of Trends In Survival And Coronary-Event Rates To Changes In Coronary Heart Disease Mortality
5. Early Heart Repair For Marfan Syndrome Patients Critical To Survival
6. Intensive Care Before A Major Op May Improve Survival
7. Sex And Survival: In Some Matters Of The Heart Women Have The Edge
8. Study: Birth Defects Decrease Survival, Childbirth, Boost Risk Of Similar Defects
9. Study Indicates That Medicare Costs Are Higher -- And Survival Rate Is Better --At Major Teaching Hospitals Survive Climate Change
10. Maxim Phase II Clinical Trial Highlights Substantial Increase In Leukemia-FreeSurvival For Acute Myelogenous Leukemia Patients
11. Beta Blocker Significantly Improves Heart Failure Survival

Post Your Comments:
(Date:7/30/2015)... ... July 30, 2015 , ... The Clinical Data Interchange Standards ... to announce that data standards for clinical research in the areas of Schizophrenia, ... website . These three Therapeutic Area (TA) standards were developed per the CDISC ...
(Date:7/30/2015)... New York, NY (PRWEB) , ... July 30, ... ... with Setria®Glutathione and Sustamine® L-Alanyl-L-Glutamine for people on the go. With no water ... Zaca Recovery Chewable as a simple way to get the natural ingredients that ...
(Date:7/30/2015)... Angeles, CA (PRWEB) , ... July 30, 2015 , ... ... cars on an upcoming dedicated web site. As discussed in a June 8, 2015 ... the minor collisions reported so far have been caused by its computer-driven cars, which ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... announce its position as one of Medicare’s top-rated care centers. The video ... the CMS rating system, which monitors health inspections, staffing, and quality measures. ...
(Date:7/30/2015)... ... July 30, 2015 , ... Zejax is a New Way ... Training Capability , World renown body weight trainer, Paul Ziachik, announces today ... dramatically increases a person’s training capability. , The American College of Sports Medicine ...
Breaking Medicine News(10 mins):Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 2Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 4Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 5Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 2Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 3Health News:Beachside Nursing Center Releases New Video 2Health News:Zejax is a Revolutionary New Way of BodyWeight Training Without Weights 2
(Date:7/30/2015)... Wash. and VANCOUVER , ... OGXI ) announced today that it will report its ... 2015. Company management will host a conference call and ... an overview of financial results, clinical development programs and ... the webcast, log on to the Investor Relations page ...
(Date:7/30/2015)... OAKS, Calif. , July 30, 2015  Amgen (NASDAQ: ... Hassan , partner and managing director of Warburg Pincus LLC, ... are pleased to welcome Fred Hassan and the ... the Amgen Board," said Robert A. Bradway , chairman ... and commitment to innovation will serve Amgen well." ...
(Date:7/30/2015)... 2015 Eisai Inc. announced today that regulatory ... States , European Union and Japan ... for eribulin, for the treatment of patients with inoperable ... for advanced or metastatic disease. These ... global Phase 3 clinical trial (Study 309), which met ...
Breaking Medicine Technology:Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
Cached News: